Neko Health Secures $700 Million Funding for Nationwide Expansion of AI Body Scans

Neko Health, a company specializing in AI body scans, has secured $700 million in funding to expand its services in the United States. The expansion will kick off with the opening of a clinic in New York, offering a comprehensive preventive screening service that includes medical imaging, blood tests, proprietary sensors, and clinician review.

The latest funding round, known as Series C, was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners. Notable existing investors like Atomico, General Catalyst, and Lakestar, as well as new backers including Liberty City Ventures, Positive Sum, and BDT & MSD, also participated in the funding.

One significant development resulting from this funding is the appointment of David Ofer from O.G. Venture Partners to Neko’s board, pending regulatory approval.

With this latest round of funding, Neko Health’s total disclosed funding since 2023 has now surpassed $1 billion. The company previously raised $65 million in a Series A round in 2023 and an additional $260 million in January 2025.

In addition to institutional investors, notable individuals such as Meta chief executive Mark Zuckerberg, Priscilla Chan, Maria Sharapova, will.i.am, Thierry Henry, Alexis Ohanian, and Zoë Saldaña have also invested in Neko Health.

Understanding Neko Health’s AI Body Scans

Neko Health operates clinics that offer full-body scans, blood tests, and AI-driven health assessments. These scans aim to detect potential health conditions such as skin cancer, cardiovascular disease, and diabetes.

The company’s service is described as a 60-minute, non-invasive health assessment that utilizes proprietary sensors, blood analysis, and advanced imaging techniques to provide a comprehensive evaluation of a customer’s health.

Key components of the scan include an electrocardiogram, arterial measurements, body composition analysis, and over 2,000 high-resolution images to map the customer’s skin. Blood samples are processed on-site for immediate results.

Following the scan, customers have an in-person consultation with a medical professional to discuss the results and any potential health concerns.

While some of the measurements provided by Neko Health are available through traditional healthcare services, the company’s integrated approach combines imaging, data collection, and clinical consultation in a single appointment.

Despite the comprehensive nature of the service, Neko has not published comparative studies to validate the effectiveness or cost-efficiency of its approach compared to conventional preventive care.

The newly secured funding will facilitate the establishment of clinics in New York and other major US cities, although specific locations and timelines have not been disclosed.

Interested individuals can join a waitlist for the New York clinic on Neko’s website, although pricing details for the US scans have not been revealed.

Currently, Neko Health operates eight clinics in the UK and Sweden, offering scans at varying prices in different locations.

Since its inception in 2023, Neko has conducted over 100,000 scans, with more than 350,000 people expressing interest in the service. Notably, 75% of customers book follow-up scans after their initial appointment.

The repeat-booking model enables clinicians to track changes in measurements and skin conditions over time, although the optimal screening interval for different age groups and risk profiles remains unclear.

Founded in 2018 by Daniel Ek and Hjalmar Nilsonne, Neko has recently expanded its offerings to include body composition measurements and wearable device data reviews in its clinics.

The company has also upgraded its medical devices to enhance data collection and automate parts of the scanning process, with plans to deploy these devices across all clinics in the near future.

Neko’s clinic-based model requires specialized equipment, on-site blood processing capabilities, trained medical staff, and expert review for certain findings. The company’s Covent Garden clinic in London, for example, was designed to accommodate tens of thousands of scans annually.

Regulation and Access in the US

Neko’s internally developed devices, including Derma-2 and Spectrum-2, received clearance from the FDA in May 2026. These devices were approved for specific uses related to skin imaging and cardiovascular measurements.

It’s important to note that FDA clearances apply to individual devices and their intended purposes rather than the overall Neko Health Scan service.

Neko Health positions its US clinics as providers of preventive health and wellness services, advising customers to consult their primary care physicians for diagnoses and treatment of any identified conditions.

Specialist clinicians, including dermatologists and cardiologists, review any findings that require further evaluation, with follow-up appointments and referrals provided as needed.

As of now, Neko’s US clinics do not participate in health insurance plans, and most services are not covered by insurance, requiring customers to pay for the initial assessment out of pocket.

The company has not disclosed pricing for diagnostic tests or treatments recommended by external healthcare providers, nor has it clarified potential subsidies from employers, insurers, or other organizations.

Concerns Regarding Clinical Evidence

Publicly available information does not include a completed peer-reviewed study validating the efficacy of Neko’s screening service. An ongoing study registered on ClinicalTrials.gov is assessing the suitability of the company’s skin-imaging technology for various applications.

Neko’s public materials do not address the frequency of false-positive results, the number of customers undergoing further procedures, or the clinical significance of flagged abnormalities.

The company utilizes AI-driven systems to summarize medical records, scan data, and clinical conversations, with reports reviewed by healthcare professionals.

While the FDA clearances pertain to specific devices, they do not encompass every algorithm used in data interpretation. Detailed real-world performance metrics for AI systems employed in the screening process are not publicly available.

Neko’s reported health outcomes from a subset of customers showed improvements in blood pressure, cholesterol, and blood sugar levels over time. However, the lack of a control group and other variables preclude definitive conclusions about the scans’ impact on these health markers.

The company’s valuation post-funding has not been disclosed officially, but reports suggest Neko may now be valued at approximately $7 billion.

(Image credit: Wonderlane)

Related: NHS AI blood test could reduce invasive womb cancer checks

For more insights on AI and big data, consider attending the AI & Big Data Expo hosted in Amsterdam, California, and London. This event, part of TechEx, brings together industry leaders and cutting-edge technologies. Learn more here.

AI News is a publication by TechForge Media, featuring upcoming enterprise technology events and webinars. Explore more events here.